Leukemia Research
Volume 24, Issue 12 , Pages 999-1008 , December 2000

Dynamic cell cycle kinetics in vitro and in vivo in myelodysplastic syndromes with special reference to the influence of hematopoietic growth factors

  • Mette Holm

      Affiliations

    • Department of Hematology, Immunhæmatologisk Laboratorium, Århus amtssygehus, Tage-Hansens Gade 2, Opgang 4A, DK 8000 Århus, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45-89497582; fax: +45-89497598
    • ,
  • Morten Høyer

      Affiliations

    • Department of Oncology, Onkologisk afdeling, Århus Kommunehospital, Nørrebrogade 44, DK 8000 Århus, Denmark
    • ,
  • Inger Jensen

      Affiliations

    • Department of Hematology, Immunhæmatologisk Laboratorium, Århus amtssygehus, Tage-Hansens Gade 2, Opgang 4A, DK 8000 Århus, Denmark
    • ,
  • Mette Thomsen

      Affiliations

    • Department of Hematology, Immunhæmatologisk Laboratorium, Århus amtssygehus, Tage-Hansens Gade 2, Opgang 4A, DK 8000 Århus, Denmark
    • ,
  • Peter Hokland

      Affiliations

    • Department of Hematology, Immunhæmatologisk Laboratorium, Århus amtssygehus, Tage-Hansens Gade 2, Opgang 4A, DK 8000 Århus, Denmark

Received 29 November 1999 ,Accepted 10 June 2000.

References 

  1. Greenberg P. The smouldering myeloid leukemic states: clinical and biological features. Blood. 1983;61:1035–1044
  2. Jacobs A, Clark R. Pathogenesis and clinical variations in the myelodysplastic syndromes. Clin. Haematol. 1986;15:925–951
  3. Janssen J, Buschle M, Layton M, Drexler H, Lyons J, van der Berghe H, et al.  Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood. 1989;73:248–254
  4. Heaney M, Golde D. Medical progress, myelodysplasia. New Engl. J. Med. 1999;340:1649–1660
  5. Jacobs A. Genetic lesions in preleukaemia. Leukemia. 1991;5:277–282
  6. Raskind W, Tirumali N, Jacobson R, Singer J, Fialkow P. Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood. 1998;63:1318–1323
  7. Sachs L. Control of growth and normal differentiation in leukemic cells: regulation of the developmental program and restoration of the normal phenotype in myeloid leukemia. J. Cell. Physiol. (Supplement). 1982;1:151–164
  8. Sanz G, Sanz M, Vallespi T. Etiopathology, prognosis and therapy of myelodysplastic syndromes. Hematol. Cell Ther. 1997;39:277–294
  9. Kerkhofs H, Hermans J, Haak H, Leeksma C. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br. J. Haematol. 1987;65:73–81
  10. Bennett J, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H, et al. Proposal for the classification of the myelodysplastic syndromes. Br. J. Haematol. 1982;51:189–199
  11. Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G, et al.  J. international scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  12. Fenaux P. Myelodysplastic syndromes. Hematol. Cell Ther. 1996;38:363–380
  13. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effects of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia (AML)) on outcome of AML-type chemotherapy. Blood. 1997;90:2969–2977
  14. De Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, et al.  Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br. J. Haematol. 1990;74:151–155
  15. Anderson J, Appelbaum F, Fisher L, Schoch G, Shulman H, Bensinger Anasetti C, et al.  Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82:677–681
  16. Oscier D. The myelodysplastic syndromes. Br. Med. J. 1997;314:883–886
  17. Ganser A, Hoelzer D. Treatment of myelodysplastic syndromes with hematopoietic growth factors. Hematol./Oncol. Clin. North Am. 1992;6:633–653
  18. Löwenberg B. Acute myelogeneous leukaemia and myelodysplasia. Baillière Clin. Haematol. 1996;9:161–183
  19. Saba H. Myelodysplastic syndromes in the elderly: the role of growth factors in management. Leuk. Res. 1996;20:203–219
  20. Mayani H, Baines P, Bowen D, Jacobs A. In vitro growth of myeloid and erythroid progenitor cells from myelodysplastic patients in response to recombinant human granulocyte-macrophage colony-stimulating factor. Leukemia. 1989;3:29–32
  21. Schipperus M, Sonneveld P, Lindemans J, Hagemeijer A, Vink N, Pegels J, et al.  The effects of interleukin-3, GM-CSF, and G-CSF on the growth kinetics of colony-forming cells in myelodysplastic syndromes. Leukemia. 1990;4:267–272
  22. Merchav S, Wagemaker G, Souza L, Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haematopoietic growth factors. Leukemia. 1991;5:340–346
  23. Koury M. Programmed cell death (Apoptosis) in hematopoiesis. Exp. Hematol. 1992;20:391–394
  24. Bradbury D, Zhy Y, Russell N. Regulation of Bcl-2 expression and apoptosis in acute myeloblastic leukaemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia. 1994;8:786–791
  25. Rinaudo M, Su K, Falk L, Haldar S, Mufson R. Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells. Blood. 1995;86:80–88
  26. Rajapaksa R, Ginzton N, Rott L, Greenberg P. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood. 1996;88:4275–4287
  27. Raza A, Gezer S, Mundle S, Gao X, Alvi S, Borok R, et al.  Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86:268–276
  28. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, et al.  A paradigm shift in myelodysplastic syndromes. Leukemia. 1996;10:1648–1652
  29. Jensen I, Hokland P. The proliferative activity of myelopoiesis in myelodysplasia evaluated by multiparameter flow cytometry. Br. J. Haematol. 1994;18:477–482
  30. Holm M, Thomsen M, Høyer M, Hokland P. Optimization of a flow cytometric method for the simultaneous measurement of cell surface antigen, DNA content and in vitro BrdUrd incorporation into normal and malignant hematopoietic cells. Cytometry. 1998;32:28–36
  31. Holm M, Thomsen M, Høyer M, Hokland P. Dynamic cell cycle kinetics of normal CD34+ cells and CD38+/− subsets of haemopoietic progenitor cells in G-CSF-mobilized peripheral blood. Br. J. Haematol. 1999;105:1002–1013
  32. Høyer M, Bentzen S, Salling L, Overgaard J. Influence of sampling time on assessment on potential doubling time. Cytometry. 1994;16:144–151
  33. Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, et al.  Fas/Apo 1(CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 1997;11:839–844
  34. Yoshida Y, Anzai N, Kawabata H. Apoptosis in myelodysplasia: a paradox or paradigm. Leuk. Res. 1995;19:887–891
  35. Raza A, Gregory S, Preisler H. The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. Leuk. Res. 1996;20:881–890
  36. Hellström-Lindberg E, Kanter-Lewensohn L, Öst Å. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk. Res. 1997;21:415–425
  37. Clark D, Lampert I. Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective haematopoiesis. Leuk. Lymph. 1990;2:415–418
  38. Lepelley P, Campergue L, Grardel N, Preudhomme C, Cosson A, Fenaux P. Is apoptosis a massive process in myelodysplastic syndromes?. Br. J. Haematol. 1996;95:368–371
  39. Raza A, Bokhari J, Tousuf N, Mehdi A, Mazewski C, Khan S, et al.  Cell cycle kinetic studies in human cancers. Arch. Pathol. Lab. Med. 1991;115:873–879
  40. Riccardi A, Danova M, Wilson G, Ucci G, Dörmer P, Mazzini G, et al.  Cell kinetics in human malignancies studied with in vivo administration of bromodeoxyuridine and flow cytometry. Cancer Res. 1988;48:6238–6245
  41. Span L, Shetty V, Broady-Robinson L, Mundle S, Alvi S, Borok R, et al.  CD34+ cells have a lower in vivo labeling index (LI) than CD34 negative cells in myelodysplastic syndromes (MDS). Blood (abstract). 1996;88(94a):365, I
  42. Kristensen J, Hokland P. Monoclonal antibody ratios in malignant myeloid diseases: diagnostic and prognostic use in myelodysplastic syndromes. Br. J. Haematol. 1990;74:270–276
  43. Raza A, Yousuf N, Bohkari S, Sheikh Y, Akhtar S, Chughtai S, et al.  In situ cell cycle kinetics in bone marrow biopsies following sequential infusions of IUdR/BrdU in patients with hematopoietic malignancies. Leuk. Res. 1992;16:299–306
  44. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia. 1993;7:144–146
  45. Williams G, Smith C, Spooncer E, Dexter T, Taylor D. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature. 1990;343:76–79
  46. Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood. 1993;82:15–21
  47. Evely R, Burnett A. ‘Differentiation therapy’ in the myelodysplastic syndromes. Leuk. Lymph. 1996;4:31–47
  48. Hellström-Lindberg E, Ahlgreen T, Beguin Y, Carlsson M, Carneskog J, Dahl I, et al.  Treatment of anaemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92:68–75
  49. Negrin R, Haeuber D, Nagler A, Kobayashi Y, Sklar J, Donlon T, et al.  Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood. 1991;76:36–43
  50. Yoshida Y, Hirashima K, Asano S, Takaku F. A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br. J. Haematol. 1991;78:378–384
  51. Geissler R, Schulte P, Ganser A. Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes. Int. J. Hematol. 1997;65:339–354
  52. Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, et al.  Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk. Res. 1996;20:891–900
  53. Brons P, Van Der Lely N, Haanen C, Pennings A, Boezeman J, Wessels J, et al.  Cell cycle kinetics of hematopoiesis before and after in vivo administration of GM-CSF in refractory anemia: evidence for a shortening of the granulocyte release time. Ann. Hematol. 1994;68:175–181

PII: S0145-2126(00)00080-1

doi: 10.1016/S0145-2126(00)00080-1

Leukemia Research
Volume 24, Issue 12 , Pages 999-1008 , December 2000

Article Tools

* Image Usage & Resolution